Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Rises By 72.6%

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 86,300 shares, an increase of 72.6% from the October 15th total of 50,000 shares. Based on an average daily volume of 831,300 shares, the short-interest ratio is currently 0.1 days. Approximately 3.2% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Monday, October 28th.

BioCardia Stock Performance

NASDAQ:BCDA opened at $2.40 on Wednesday. The stock’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $3.37. BioCardia has a 1 year low of $1.96 and a 1 year high of $23.25.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.78). On average, analysts expect that BioCardia will post -5.06 EPS for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.